Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis
Metrics: PDF 1703 views | HTML 2469 views | ?
Ji Wang1,2,*, Chenyang Ye3,*, Demin Lu3,4,*, Yongxia Chen1,2, Yunlu Jia1,2, Xiaogang Ying1,2, Hanchu Xiong1,2, Wenhe Zhao1,2, Jichun Zhou1,2 and Linbo Wang1,2
1Department of Surgical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China
2Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, Zhejiang, 310016, China
3Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China
4Department of Medical Oncology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310009, China
*These authors have contributed equally to this work
Wenhe Zhao, email: [email protected]
Jichun Zhou, email: [email protected]
Linbo Wang, email: [email protected]
Keywords: MMP1, breast cancer, immunohistochemistry, prognosis, overall survival
Received: June 27, 2017 Accepted: August 04, 2017 Published: August 24, 2017
Matrix metalloproteinase-1 (MMP1) is a member of the matrix metalloproteinases family, and its aberrant expression is implicated in tumor invasion and metastasis. However, the relationship between MMP1 abnormal expression and clinical outcome in breast cancer patients remains to be elucidated. To address this issue, we conducted immunohistochemistry in breast cancer and adjacent normal tissues, and mined the transcriptional and survival data of MMP1 in breast cancer patients through Oncomine, Kaplan-Meier Plotter, bc-GenExMiner, COSMIC and cBioPortal databases. First, we found that both protein and mRNA levels of MMP1 expression were significantly higher in breast cancer tissues. Second, high MMP1 mRNA expression correlated with worse overall survival among grade II (HR = 1.75; p = 0.011), nodal-negative (HR = 2.00; p = 0.00028), ER-positive (HR = 1.61; p = 0.00027) and HER2-negative (HR = 3.17; p = 0.029) patients with breast cancer by using Kaplan-Meier plotter database. Third, the overexpression of MMP1 was associated with unfavorable survival results including overall survival (HR = 1.6; p = 1.6e-05), relapse free survival (HR = 1.78; p < 1e-16) and distant metastasis free survival (HR = 1.65; p = 5.3e-05) in patients with breast cancer. Taken together, the expression status of MMP1 is a significant prognostic indicator and a potential drug target for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.